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When used in pregnancy, immunosuppressants can cross the placental barrier and enter foetal circulation, 
possibly affecting the immune system of the foetus. This study evaluated the immune function in eight 
children born by mothers with connective tissue diseases who received immunosuppressants (cyclosporine 
A or dexamethasone) during pregnancy and in six babies from mothers with similar diseases, but who 
did not receive any treatment. Judging by the cytokine production of interleukin-2 and interferon-γ in 
peripheral blood mononuclear cells stimulated by phorbol-myristate-acetate (PMA) and ionomycin, 
immunosuppressive drugs given for rheumatic disorders during pregnancy do not induce significant 
immunosuppression in babies.
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Ideally, no drug should be used in pregnancy, and 
immunosuppressive agents in particular. However, 
transplantation and the treatment of connective 
tissue diseases often require the use of these drugs 
both to protect the mother and to ensure successful 
pregnancy.
The effects of glucocorticoids on the foetus differ 
from drug to drug; prednisone is inactivated before 
it can reach foetal tissue while synthetic fluorinated 
steroids such as betamethasone and dexamethasone 
are not. Cyclosporine A crosses the placental barrier 
and can be measured in foetal blood. Literature 
reports impairments of immunologic development 
in up to one year old infants (1). 
The aim of this open study was to evaluate the 
immune function of newborns whose mothers had 




In our high-risk pregnancy clinic, all children born 
to mothers with autoimmune diseases are usually 
followed until they complete the first year of life. This 
study included nine babies (four boys and five girls) 
born to mothers with autoimmune diseases who 
had been receiving immunosuppressants during 
pregnancy. These women were affected by systemic 
lupus erythematosus (n=2), psoriatic arthritis (n=1), 
and subacute cutaneous lupus (n=1), while two 
women were healthy. The latter had been treated 
with fluorinated corticosteroids during pregnancy 
because of a complete foetal heart block associated 
with anti-SSA/Ro autoantibodies. One woman gave 
birth to twins and the other to triplets. The children 
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were followed in the Paediatric Department of Milan 
University in 2002-2003. The control group consisted 
of 14 children (five boys and nine girls) born to 
mothers with autoimmune disorders (mainly systemic 
lupus erythematosus and Sjögren syndrome) who 
had not been receiving immunosuppressants during 
pregnancy. Table 1 shows the diagnosis and the 
immunosuppressive therapy for mothers who received 
it during pregnancy. Mothers of two children (nos. 2 
and 3) were also taking prednisone, while one (of child 
no. 3) was also taking hydroxychloroquine.
Mothers of infants in the control group were not 
taking medications for their underlying disorder during 
pregnancy, but some received hydroxychloroquine 
(four mothers), baby-aspirin or a low-dose (≤10 mg 
day-1) prednisone (mostly inactivated before reaching 
the foetus).
Methods
Eight exposed infants and six controls were 
tested for interleukin-2 (IL-2) and interferon-gamma 
(IFN-γ) production by peripheral blood mononuclear 
cells using the quantitative sandwich ELISA method 
(R&D Systems, Minneapolis, MN, USA). Cytokine 
concentrations were evaluated in supernatants from 
unstimulated or 48-hour stimulated cell cultures 
(phorbol-myristate-acetate, PMA, 5 ng mL-1, ionomy-
cin, 500 ng mL-1 and PMA + ionomycin). Informed 
parental consent and approval by the hospital ethical 
committee were obtained for the study. The results 
of the exposed and control subjects were compared 
using the chi-square test with correction for multiple 
comparisons where appropriate.
RESULTS
No significant difference in any of the parameters 
evaluated was found between the infants of mothers 
who were receiving immunosuppressive therapy during 
pregnancy and those who were not (2). Complete 
blood count was normal in all subjects, except for two 
infants with anaemia (one exposed and one control) 
and one with a mild thrombocytopenia (exposed). 
According to the chi-square test, lymphocyte 
subpopulations, immunoglobulin serum levels, and 
IgG subclasses did not significantly differ between the 
exposed and control group. All infants who received at 
least one dose of hepatitis B vaccine (recombinant hep 
B) reached a protective antibody titre (>10 mIU mL-1) 
(2). Figures 1 and 2 show our preliminary laboratory 
findings for cytokine (IL-2 and IFN-γ) production by 
peripheral blood mononuclear cells in the exposed 
subjects and controls. Even though the number of 
subjects is small, these data seem to suggest that 
cytokine production might be impaired in infants 
exposed to cyclosporine in utero.
Figure 1 Individual IL-2 production (pg mL-1) by peripheral blood 
mononuclear cells stimulated with phorbol-myristate-acetate 
+ ionomycin. Each bar represents one subject: CyA - subjects 
exposed to cyclosporine A in utero; Dex - subjects exposed to 
dexamethasone in utero; Ctr – control subjects.
Table 1 Maternal diagnosis and the therapy of the mothers receiving immunosuppressants during pregnancy.
Subject no. Dx          Tx Daily dose / mg Durationweeks
Cumulative
dose / mg
1 PsA Cyclosporine A 2 x 100 37 51800
2 SLE Cyclosporine A 150 38 39000
3 Healthy Dexamethasone 4 9 252
4 (twin) SCL Dexamethasone 4  0.5* 10 173
5 (twin) Dexamethasone 4  0.5* 10 173
6 (triplet) Healthy Dexamethasone 4 16 448
7 (triplet) Dexamethasone 4 16 448
8 (triplet) Dexamethasone 4 16 448
Dx = maternal diagnosis; Tx = maternal treatment; PsA = Psoriatic arthritis; SLE = systemic lupus erythematosus; SCL = subacute cutaneous lupus.
* 4 mg/day for  4 weeks, than 2 mg/day for 2 weeks, than 1 mg/day for 2 weeks, than 0,5 mg/day for 2 weeks
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DISCUSSION
Immunosuppressive drugs given to pregnant 
women usually cross the placental barrier and 
pass to the foetus. Immunosuppressed pregnant 
women run an increased risk of both foetal and 
maternal complications (premature birth, intrauterine 
growth retardation, congenital malformations 
and pre-eclampsia, respectively). The effects of 
immunosuppressive and anti-rheumatic agents on 
pregnancy have been reviewed extensively (3-10).
Until recently, the effects of immunosuppression 
on foetal and neonatal immune system have not 
been studied, and most of the published data refer to 
transplant recipients (11-13). We therefore conducted 
a pilot study in order to evaluate these effects in 
children born from patients with autoimmune 
disorders, and found no relevant effect on their 
immune function, as evaluated by immunoglobulin 
concentrations, lymphocyte subpopulations, and 
response to hepatitis B vaccination.
Our study included children whose mothers had 
been treated with corticosteroids as well as children 
who were exposed to active dexamethasone in order 
to treat their congenital heart block. Cyclosporine 
A (CyA), an immunosuppressant used mainly in 
transplantation, can readily cross the placental 
barrier, and foetal plasma levels can reach more 
than half the maternal serum levels (14). Several 
authors studied the effects of CyA (15-23) and of a 
related compound tacrolimus on pregnancy (24, 25). 
Cyclosporine A is also excreted in breast milk and 
can be found in neonatal blood after nursing (26, 
27). Padgett and Seelig (28) studied the lactational 
transfer of CyA in an animal model, and found 
significant alterations in T-cell maturation and the 
inhibition of lymphoproliferative response to antigen 
activation, indicating a potential for an increased 
risk of opportunistic infections. Pilarski et al. (29) 
analysed peripheral blood lymphocytes collected from 
infants exposed to cyclosporine A and azathioprine 
in utero and found alterations in activated and 
memory T-cell count. Di Paolo et al. (1) also studied 
lymphocyte subpopulations and immunoglobulin 
levels in infants exposed to cyclosporine in utero. 
Total B-cell and T-cell counts (as well as CD4+ and 
CD8+ cell counts) were low at birth, but normalised 
thereafter. T-cell activation markers such as the alpha 
chain of interleukin-2 receptor (CD25) and HLA-DR 
expression were low throughout the study period (up 
to one year of age). IgG serum levels were normal at 
birth, but IgA and IgM concentrations were low. In the 
second month of age, IgG1 and IgG3 subclass levels 
were low, and remained low up to the sixth month of 
age. These infants did not develop opportunistic or 
chronic infections and had a normal growth during 
their first year of life. However, the authors suggest 
that conventional vaccination should be postponed in 
these infants. In our study, the immune parameters of 
the exposed infants, some of whom to Cyclosporine 
A, kept within the normal range, and the antibody 
response to hepatitis B vaccination was normal in 
all cases, which suggests that the immunologic 
response to vaccines is not impaired (2). A normal 
IgG antibody response to vaccination has been 
demonstrated earlier (30), which is in agreement with 
our results. Moreover, a recent case report describes 
normal immune development, including normal 
serum immunoglobulin levels and normal response to 
tetanus and hepatitis B vaccinations in a child exposed 
to Cyclosporine A in utero (31).
Literature also describes immunosuppressed 
newborns exposed to azathioprine in utero. This 
drug is known to cross the placental barrier (32-
35). Notably, the foetus is protected from its effects 
during organogenesis, since it lacks the liver enzyme 
that converts azathioprine to its active metabolites. 
As Cyclophosphamide is contraindicated during 
pregnancy, there are no studies available on its effects. 
While methotrexate is also contraindicated during 
pregnancy, there have been case reports of successful 
pregnancies in women who inadvertently got pregnant 
while on this drug.
Exposure to immunosuppressants in utero raises 
the issue of possible increased susceptibility to 
Figure 2 Individual IFN-γ production (pg mL-1) by peripheral blood 
mononuclear cells stimulated with phorbol-myristate-acetate 
+ ionomycin. Each bar represents one subject: CyA - subjects 
exposed to cyclosporine A in utero; Dex - subjects exposed to 
dexamethasone in utero; Ctr – control subjects.
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autoimmune diseases later in life (36-38). In fact, it 
might impair the ability of the foetal immune system to 
delete autoreactive T-cells, and immunosuppressants 
such as CyA have been shown to be able to break self-
tolerance by interfering with the production of CD4+ 
and CD8+ cells in the foetal thymus. In addition, CyA 
can inhibit the activation of potentially self-reactive T-
cells, thereby down-regulating these “autoimmune” 
clones. On the other hand, discontinued exposure 
could allow autoimmunity to develop and progress. 
Indeed, lethally irradiated rodents exposed to CyA 
during immune reconstitution (post-syngeneic bone 
marrow transplant) developed a T-cell-mediated 
autoimmune disease (39). Another report refers 
to a case of ulcerative colitis and systemic lupus 
erythematosus in a girl exposed to azathioprine in utero 
(40). The effect of altered thymocyte differentiation 
during negative selection of autoreactive T-cells that 
was seen in rodents appeared to be related to the 
down-regulation of thymic MHC class II molecules 
(39,41). Until now, none of the children in our study 
have developed new autoantibodies.
The developing immune system has been shown 
to be affected by maternal cortisol secretion, resulting 
in an increased susceptibility to asthma and atopy in 
genetically predisposed individuals (42). This has been 
thought to be secondary to a Th1/Th2 differentiation 
imbalance, and steroid treatment during pregnancy, 
particularly when the fluorinated steroids are used, 
could theoretically drive the balance toward a Th2-
like response (43, 44). We will therefore continue to 
follow the children described in this study for possible 
development of autoimmune and/or atopic disorders 
during their childhood and adolescence.
CONCLUSION
Immunosuppressive therapy of rheumatic disorders 
during pregnancy does not seem to induce significant 
immunosuppression in babies. However, this issue 
requires further investigation. Data from long-term 
follow-up of infants exposed to immunosuppressants 
in utero are still too limited to exclude possible 
development of autoimmune diseases later in life.
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Sažetak
IN VIVO UTJECAJ IMUNOSUPRESIJE U MAJKI ZA VRIJEME TRUDNOÆE NA IMUNOSNI 
SUSTAV NOVOROĐENÈADI
Imunosupresivni lijekovi davani za vrijeme trudnoæe mogu proæi placentalnu barijeru i uæi u cirkulaciju 
fetusa, s moguæim utjecajem na njegov imunosni sustav. U radu je praæena imunosna funkcija kod osmero 
djece roðene od majki s bolestima vezivnog tkiva, koje su tretirane za vrijeme trudnoæe imunosupresivnim 
lijekovima (ciklosporin A ili deksametazon) i kod osmero novoroðenèadi roðene od majki sa sliènim 
bolestima, ali koje nisu bile tretirane. Imunosupresivni lijekovi primijenjeni za vrijeme trudnoæe kod majki koje 
boluju od reumatskih bolesti ne izazivaju znaèajniju imunosupresiju u novoroðenèadi praæenu nastajanjem 
citokina, interleukina 2 i interferona γ  u perifernim mononuklearnim krvnim stanicama pod djelovanjem 
forbol-miristat-acetata (PMA) i ionomicina.
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